Fresenius Kabi USA has launched Levofloxacin in 5% Dextrose Injection in freeflex containers. Freeflex is designed for infusion solutions and has been marketed globally since 2005. Freeflex has multilayer polyolefin film that is PVC-free, plasticizer-free, non-DEHP, and is designed for easier handling with enhanced safety, and environmental performance.
Levofloxacin is a fluoroquinolone antibacterial indicated for use in the treatment of bacterial infections caused by susceptible bacteria, including pneumonia, bronchitis, skin infections, urinary tract infections, prostatitis and anthrax.
“The introduction of Levofloxacin using the freeflex technology expands our market leading anti-infective business with a ready to use formulation and provides customers with a new choice in serving their patients,” said John Ducker, president and chief executive officer of Fresenius Kabi USA.
Fresenius Kabi Launches Levofloxacin Freeflex IV
Published August 30, 2013
blog comments powered by Disqus